Enhanced resistance to herpes simplex virus type 1 infection in transgenic mice expressing a soluble form of herpesvirus entry mediator  by Ono, Etsuro et al.
www.elsevier.com/locate/yviro
Virology 320 (2004) 267–275Enhanced resistance to herpes simplex virus type 1 infection in transgenic
mice expressing a soluble form of herpesvirus entry mediator
Etsuro Ono,a,* Saori Yoshino,a,b Keiko Amagai,a,c Satoshi Taharaguchi,a Chiemi Kimura,d
Junko Morimoto,d Manabu Inobe,d Tomoko Uenishi,d and Toshimitsu Ueded
aLaboratory of Animal Experiment for Disease Model, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
bGene Techno Science, Sapporo 062-8517, Japan
cSankyo Labo Service Corporation, Tokyo 132-0023, Japan
dDivision of Molecular Immunology, Research Section of Molecular Pathogenesis, Institute for Genetic Medicine, Hokkaido University,
Sapporo 060-0815, JapanReceived 29 July 2003; returned to author for revision 14 November 2003; accepted 24 November 2003Abstract
Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor (TNF) receptor family used as a cellular receptor by virion
glycoprotein D (gD) of herpes simplex virus (HSV). Both human and mouse forms of HVEM can mediate entry of HSV-1 but have no entry
activity for pseudorabies virus (PRV). To assess the antiviral potential of HVEM in vivo, three transgenic mouse lines expressing a soluble
form of HVEM (HVEMIg) consisting of an extracellular domain of murine HVEM and the Fc portion of human IgG1 were generated. All of
the transgenic mouse lines showed marked resistance to HSV-1 infection when the mice were challenged intraperitoneally with HSV-1, but not
to PRV infection. The present results demonstrate that HVEMIg is able to exert a significant antiviral effect against HSV-1 infection in vivo.
D 2004 Elsevier Inc. All rights reserved.Keywords: Herpesvirus entry mediator; HveA; HVEM; HSV-1; Transgenic mouseIntroduction
Herpesviruses have been classified into three subfamilies
on the basis of biological characteristics and genomic anal-
ysis. Members of the alphaherpesvirus subfamily including
human herpes simplex virus types 1 and 2 (HSV-1 and HSV-
2), porcine pseudorabies virus (PRV), and bovine herpesvi-
rus 1 (BHV-1) as representative members are neurotropic,
have a short replicative cycle, and have a broad host range.
Infection in the natural host is characterized by lesions in the
epidermis, usually on mucosal surface, with spread of virus
to the nervous system and establishment of latent infections
in neurons.
Binding of alphaherpesviruses to cells occurs primarily
through an interaction of virion glycoproteins (gC and/or
gB) with cell surface heparan sulfate (Herold et al., 1994;
Mettenleiter et al., 1990; Shieh et al., 1992; WuDunn and0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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and cell membrane requires the glycoproteins gB, gD, gH,
and gL (Cai et al., 1988; Forrester et al., 1992; Ligas and
Johnson, 1988; Roop et al., 1993). The interaction be-
tween HSV envelope gD and a specific cellular receptor is
required for virus entry into mammalian cells (Campadelli-
Fiume et al., 2000; Spear et al., 2000). To date, five
human alphaherpesvirus receptors have been identified:
herpesvirus entry mediator (HVEM, also known as HveA
and TNFRSF14), a TNF receptor-related protein (Mont-
gomery et al., 1996); three immunoglobulin superfamily
members: HveB (PRR2, nectin-2), HveC (PRR1, nectin-
1), and HveD (PVR, CD155); and 3-O-sulfated heparan
sulfate (Cocchi et al., 1998; Geraghty et al., 1998; Shukla
et al., 1999; Warner et al., 1998). HVEM was identified as
a gD receptor for entry of HSV-1 and HSV-2 (Montgom-
ery et al., 1996; Nicola et al., 1998; Whitbeck et al.,
1997).
HVEM is expressed in lymphoid cells but also in other
cell types (Kwon et al., 1997; Montgomery et al., 1996).
Mice encode a related protein that is only 45% identical to
Fig. 1. Western blot analysis of tail extracts from the transgenic and non-
transgenic mice. The positive control (HVEMIg) is the purified HVEMIg
from the supernatant of COS7 cells infected with AxHVEMIg. The
positions of molecular size markers are shown, along with the expected
position of HVEMIg.
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forms of HVEM can mediate entry of HSV-1 and HSV-2 but
have no entry activity for PRV and BHV-1 (Montgomery et
al., 1996; Spear et al., 2000). Natural ligands for HVEM are
members of the TNF family including lymphotoxin-a and
LIGHT (Mauri et al., 1998). Both can also serve as ligandsFig. 2. Resistance to HSV-1 infection in the transgenic mouse lines A (A), B (B), a
mice were challenged intravenously with HSV-1. In a control experiment, transgen
mice were observed for their survival times, which are recorded daily for 14 sucfor other members of the TNF receptor family. The cyto-
plasmic tail of HVEM can transmit signals through TNF
receptor-associated factors (TRAFs) resulting, for example,
in activation of NF-nB and AP1 (Hsu et al., 1997; Marsters
et al., 1997). LIGHTcan stimulate the proliferation of T cells,
presumably through interactions with HVEM (Harrop et al.,
1998a; Kwon et al., 1997). Deletion of the cytoplasmic tail
from HVEM to remove all TRAF-binding sequences has no
effect on the ability of HVEM to mediate HSV entry
(Montgomery et al., 1996). Thus, signal transduction seems
not to be required for viral entry, although signal transduc-
tion might occur when HSV enters a cell via full-length
HVEM and thus influence downstream events in viral
replication or virus–cell interaction.
We have set our sights on inhibition of viral entry for the
approach to germ-line transformation in animals to confer
resistance to virus infection. It has been shown that secreted
forms of HVEM bind to the virus by an interaction with
HSV-1 gD and block infection by HSV-1 (Geraghty et al.,
1998; Nicola et al., 1998; Whitbeck et al., 1997). In the
present study, transgenic mouse lines expressing a soluble
form of HVEM were established and resistance to HSV-1
infection in the transgenic mice was then examined to
determine the antiviral potential of the soluble form of
HVEM in vivo.nd C (C). The transgenic (closed squares) and non-transgenic (open squares)
ic mice of the line A and C57BL/6 mice were challenged with PRV (D). The
cessive days after the challenge.
Fig. 3. Histopathological analyses of mouse brains infected with HSV-1.
The non-transgenic mouse brain (A) and the transgenic mouse brain (B)
infected with HSV-1, and a mock-infected control mouse brain (C) in
sagittal sections were stained with hematoxylin and eosin.
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Characterization of transgenic mice
To assess the antiviral potential of HVEM in vivo, we
generated three transgenic mouse lines expressing a soluble
form of HVEM (HVEMIg) consisting of an extracellular
domain of murine HVEM and the Fc portion of human IgG1.
In these transgenic mice, HVEMIg was expressed under the
control of the CAG promoter, which is expected to allow
ubiquitous expression in all cell types (Niwa et al., 1991). To
prepare HVEMIg, an adenovirus vector containing the
HVEMIg gene (AxHVEMIg) was constructed. HVEMIg
was purified from the supernatant of AxHVEMIg-infected
COS7 cells by Protein A-Sepharose. A specific band whose
molecular size is comparable to that of purified HVEMIg
was detected by Western blot analysis using rabbit anti-
HVEMIg antibody in each transgenic mouse line (Fig. 1).
HVEMIg concentrations in serum samples of the transgenic
mouse line Awere 17.3–29.6 Ag/ml, those of the lines B and
C were 4.4–8.5 Ag/ml and 14.2–24.3 Ag/ml, respectively.
Resistance to HSV-1 infection in the transgenic mice
To find out whether the transgenic mice expressing
HVEMIg were protected from HSV-1 infection, 10 LD50
of HSV-1 determined on C57BL/6 mice was intravenously
inoculated into the transgenic mice and their non-transgenic
littermates. Because these transgenic founders were obtained
from B6SJLF1 (C57BL/6 X SJL) mouse embryos and the
offspring of a heterozygous of the F3 progeny and C57BL/6
parents were used for the experimental infection, the 50%
lethal doses of HSV-1 were determined on C57BL/6 and SJL
mice. The LD50 of HSV-1 on C57BL/6 and SJL mice were
108 and 107 PFU, respectively. Based on the results, 109 PFU
of HSV-1 was inoculated into the mice. The survival data
(Fig. 2) demonstrate that all of the transgenic mouse lines
showed remarkable resistance to HSV-1 infection. All of
transgenic mice of the line A completely survived the viral
inoculation and remained healthy for several months follow-
ing this trial. In contrast, seven of nine littermates of the line
A developed symptoms such as paralysis or died within 14
days after HSV-1 infection. Only one transgenic mouse of
the line B, which is low expression line, died after the
infection and other six transgenic mice survived. In contrast,
13 of 14 littermates of the line B developed the symptoms or
died within 14 days. In the line C, all of the transgenic mice
completely survived the viral inoculation, and six of seven
littermates of the line C developed the symptoms or died. To
confirm whether signs of disease such as paralysis were due
to encephalitis caused by HSV-1 infection, histopathological
analyses were performed. As shown in Fig. 3A, brains
obtained from the non-transgenic mice infected with HSV-
1 exhibited typical encephalitic lesions such as perivascular
cellular infiltration, gliosis, and neuronal degeneration. In
contract, such severe lesions were not observed in thetransgenic mice infected with HSV-1 (Fig. 3B) as in mock-
infected control mice (Fig. 3C). During latent infection,
HSV-1 LATs are detected in the trigeminal ganglia (Spivak
and Fraser, 1987; Stevens and Cook, 1971). RT-PCR anal-
ysis was performed to detect LATs in the trigeminal ganglia
of survived mice. LATs expression was observed in all of the
recovered littermates that developed the symptoms and only
one transgenic mouse of the line B that exhibited no
symptom, but not in all of other transgenic mice and the
survived littermates without symptom. In a control experi-
Table 1
Inhibition of HSV-1 infection by HVEMIg in sera of the transgenic mice
Serum (HVEMIg Ag/ml)a Plaque numberb
HSV-1 PRV
C2 (14.2) 0 58.0 F 8.8
(1.42) 0 NT
(0.14) 1.7 F 1.6 NT
(0.01) 34.7 F 16.2 NT
C2 (0.14) + anti-HVEMIg 30.3 F 6.9 NT
Control 44.0 F 0 53.7 F 2.9
a Determined by competitive ELISA.
b The value is the average of triplicated infections and standard deviation is
shown.
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HVEMIg were protected from PRV infection, 10 LD50 (viral
dose determined on C57BL/6 mice; 250 PFU) of PRV was
intravenously inoculated into transgenic mice of the line A
and C57BL/6 mice because HVEM dose not act as a gD
receptor for PRV. All of the transgenic and control mice died
within 10 days after PRV infection (Fig. 2D). The mice used
in these challenge experiments were the offspring of hetero-
zygous transgenic and non-transgenic parents. The use of
non-transgenic littermates as negative controls in these
experiments minimizes the possible contributions of varia-
bles not associated with the presence of the transgene. It is,
therefore, considered that the only difference between ex-
perimental and control animals is the presence of the
functional HVEMIg gene in the transgenic animals which
showed marked resistance to HSV-1 infection.
Because herpesviruses usually enter the body via infec-
tion of mucosal epithelium, RT-PCR analysis was performed
to detect LATs in the trigeminal ganglia of mice after
intranasal inoculation with 104 PFU of HSV-1. As shown
in Fig. 4, LATs expression was not observed in 17 of 22
transgenic mice. In contrast, eight of nine littermates were
infected with HSV-1. In the virus inoculation with 106 PFU
of HSV-1, however, all of the transgenic mice were infected
with HSV-1 in addition to their littermates (data not shown).
Unfortunately, even in the highest dose tested, no symptom
was developed by the intranasal inoculation. These results
indicate that expression of HVEMIg protects from HSV-1
infection via mucosal inoculation and the protection depends
on the virus dose.
Inhibition of HSV-1 infection by HVEMIg in sera of the
transgenic mice
To examine the antiviral activity in sera of the transgenic
mice, a virus plaque reduction assay was performed. It was
found that sera of the transgenic mouse line C protected Vero
cells against HSV-1 infection but not PRV infection. In
contrast, sera of non-transgenic mouse failed to show any
protection against both virus infections. This antiviral activ-
ity was neutralized by preincubation with the rabbit anti-Fig. 4. Expression of LATs in the trigeminal ganglia of mice after intranasal inocul
mice of line C and their littermates was examined by RT-PCR 2–3 weeks after
performed using the LATs-specific probes. The positive control (+) is a product s
control ( ) is a product from that of mock-infected Vero cells.HVEMIg antibody. In addition, level of the antiviral activity
was correlated with the concentrations of HVEMIg in serum.
The results of plaque assays were presented in Table 1. In the
assays using sera of other transgenic mice, similar inhibition
was observed. These results demonstrated that HVEMIg in
sera of the transgenic mice is able to inhibit HSV-1 infection.
Inhibition of HSV-1 infection in cultured embryonic
fibroblasts from the transgenic mice
To assess whether the in vivo resistance to HSV-1
infection in the transgenic mice was paralleled by resistance
of their isolated cells, we tested embryonic fibroblasts for
resistance to HSV-1 infection in culture. Transgenic and
non-transgenic embryo fibroblasts were prepared from em-
bryos of the heterozygous transgenic (the line B) and non-
transgenic parents. HVEMIg expression in the transgenic
fibroblasts was confirmed by Western blot analysis, whereas
HVEMIg was not detected in the non-transgenic fibroblasts
(Fig. 5A). The transgenic and non-transgenic fibroblasts
were infected with 50 PFU of HSV-1. In the transgenic
fibroblasts, number of plaques was extensively suppressed
as compared with the non-transgenic fibroblasts 5 days
postinfection (Fig. 5B). In contrast, there was no difference
between the transgenic and non-transgenic fibroblasts
infected with PRV (Fig. 5B). To monitor virus growth in
the transgenic fibroblasts, virus infectivities in the mediaation of HSV-1. LATs expression in the trigeminal ganglia of the transgenic
the virus inoculation. Southern blot analysis of the RT-PCR products was
ynthesized from the total RNA of PRV-infected Vero cells and the negative
Fig. 5. Resistance to HSV-1 infection in embryonic fibroblasts prepared
from the transgenic mice. (A) Western blot analysis of cell extracts from the
transgenic (Tg) and non-transgenic (Non-Tg) fibroblasts. The positive
control (HVEMIg) is the purified HVEMIg from the supernatant of COS7
cells infected with AXHVEMIg. (B) Plaque assays of HSV-1 and PRV
infection on the embryonic fibroblasts. Plaque assays were performed as
described in Materials and methods. (C) HSV-1 and PRV growth curves in
embryonic fibroblasts prepared from the transgenic (closed squares) and
non-transgenic (open squares) mice.
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yield was extensively suppressed (100-fold less in virus titer
than the non-transgenic fibroblasts 2 and 3 days postinfec-
tion). The transgenic fibroblasts were susceptible to infec-
tion with PRV as the non-transgenic fibroblasts (Fig. 5C).
These results indicate that HVEMIg expressed from the
transgenic fibroblasts specifically inhibit HSV-1 infection to
the fibroblasts.Discussion
Infections of HSV-1 are highly prevalent among humans.
Pathologic manifestations vary from mucocutaneous lesions
of the mouth, face, eyes, or genitals, to involvement of
central nervous system, resulting sometimes in encephalitis
(Whitley, 1996). In the present study, transgenic mice
expressing HVEMIg showed significant resistance to
HSV-1 infection when the mice were challenged intraper-
itoneally with HSV-1. This resistance was much more
striking than that observed in HSV-1-resistant transgenic
mouse lines expressing a mutant allele (X25) of ICP4
(Smith and DeLuca, 1992). The demonstration that HVE-
MIg secreted into sera of the transgenic mice is sufficient to
compete with the virus infectivity may provide a basis forthe future development of a novel class of anti-HSV agent
designed specifically to block HSV-1 infection.
Consistent with the earlier studies (Geraghty et al., 1998;
Nicola et al., 1998; Whitbeck et al., 1997), a secreted form of
HVEM, HVEMIg, in sera of the transgenic mice blocked
HSV-1 infection. In addition, the transgenic embryonic
fibroblasts showed marked resistance to HSV-1 infection.
These results indicate that secreted HVEMIg may have
important roles on the resistance to HSV-1 infection in the
transgenic mice. Almost complete protection from intrave-
nous infection may suggest a possibility that the primary
effect of the fusion protein is to bind to virus in serum and
promote its clearance by macrophage via the Fc portion of
human IgG. This effect of the fusion may enhance the
resistance to the virus infection in vivo. LATs expression
in the trigeminal ganglia was not detected in the survived
transgenic mice except for only one transgenic mouse of the
line B, indicating that protection against intravenous infec-
tion with HSV-1 in the transgenic mice was almost complete.
Likely, the transgenic mouse of the line B expressing LATs
was infected with HSV-1. This finding suggests that HVE-
MIg may suppress manifestation of the disease. Only two
transgenic mice of the line B, the lowest expression line,
were infected and only one mouse died, indicating that the
level of resistance to HSV-1 infection may be correlated with
the concentrations of HVEMIg in serum.
Protection from intranasal HSV-1 infection was proved
by RT-PCR analysis for detection of LATs expression in the
trigeminal ganglia. In 75% of transgenic mice inoculated
intranasally with HSV-1, LATs expression was not detected.
In contrast, more than 90% of non-transgenic littermates
allowed to the virus infection (Fig. 4). However, transgenic
mice inoculated with higher doses of HSV-1 could not
prevent the viral infection. These findings indicate that
transgenic mice expressing HVEMIg may be able to prevent
HSV-1 entry into the body via mucosal epithelium, in
addition to intravenous rote.
HSV infections in mice are influenced by the host genetic
background, and multiple dominantly inherited genes are
involved (Lopez, 1975). Although these results have been
known for a long period of time, no particular host gene that
can control the outcome of experimental HSV-1 infection in
mice has so far been identified. The effectiveness of resis-
tance mechanisms is not only age dependent, but also re-
gulated by genetic factors that are generally virus specific. In
adult mice, the resistance to HSV-1 infection is regulated by
non-H-2 genes (Lopez, 1975, 1980). For HSV-1, C57BL/6
mice are genetically resistant (Kumel et al., 1982; Zwatzky et
al., 1982). Because our transgenic mice may contain the
HSV-1-resistant background, we cannot completely exclude
a possibility that the genetic control of resistance to HSV-1
infection may be involved in the observed resistance in the
transgenic mice. However, susceptibility of their non-trans-
genic littermates to HSV-1 infection was demonstrated in the
present study. Furthermore, all of the transgenic mouse lines
showedmarked resistance to HSV-1 infection. It is, therefore,
E. Ono et al. / Virology 320 (2004) 267–275272considered that resistance to HSV-1 infection in the transge-
nic mice was conferred by the manipulation of only one gene.
The major concern in the transgenic mice is adverse side
effects caused by the expressed HVEMIg. However, we
observed no gross abnormality while breeding the transgenic
mouse lines. The transgenic mice developed normally and
there was no difference in the body weights of the transgenic
mice and their non-transgenic littermates. HVEM is a mem-
ber of the tumor necrosis factor (TNF) receptor family and a
receptor for lymphotoxin-a (LTa) and LIGHT (Mauri et al.,
1998) and plays an important role on the immune systems. A
possibility is that HVEMIg affects the host immune
responses against the insulting agents because HVEMIg
can also block the binding between HVEM and LIGHT,
resulting in the inhibition of T cell activation (Harrop et al.,
1998b). Although the possibility could not be eliminated in
the transgenic mice used in the present study, significant
difference in the immune responses was not observed, at
least when the transgenic and non-transgenic mice were
immunized with ovalbumin (data not shown). It seems likely
that fatal disturbances of the immune responses do not occur
in the transgenic mouse lines.
The animals described herein expressing HVEMIg con-
stitutively demonstrated significant resistance to HSV-1
challenge. It is noteworthy that protection against HSV-1
entry in the sites of primary infection was observed in the
transgenic mice via intranasal inoculation of HSV-1. The
potential that suppresses HSV-1 replication in the embry-
onic fibroblasts may support this finding. Several possible
effects of HVEMIg on the suppression of virus replication
in the primary fibroblasts are considered. First, HVEMIg
inhibits initial infection to the fibroblasts. Second, HVEMIg
also inhibits secondary infections of the fibroblasts with free
virus released in the first round infection. Third, HVEMIg
inhibits secondary infection in the fibroblasts mediated by
cell to cell spread. These possible effects of HVEMIg on the
nasal mucosa could be considered, resulting in protection
from HSV-1 infection.
Adverse side effects such as toxicity and infertility were
characteristic of herpesvirus-resistant transgenic mice (Ono
et al., 1999; Smith and DeLuca, 1992). However, no side
effect is observed in the three transgenic mouse lines. These
transgenic mouse lines showed normal growth rates and
they are fertile. Therefore, it may be possible to use similar
kind of transgenes encoding soluble forms of the receptors
for an approach to germ-line transformation in agricultural
livestock to confer resistance to animal herpesvirus infection
such as pseudorabies virus.Materials and methods
Virus and cells
Herpes simplex virus type 1 (HSV-1) strain VR-3 was
kindly provided by T. Suzutani (Asahikawa Medical Col-lege, Asahikawa, Japan). Vero cells were a generous gift
from M. Peeples (Rush University, Chicago, IL). Vero cells,
grown in RPMI1640 medium supplemented with 5% fetal
bovine serum, 0.03% L-glutamine, 100U/ml penicillin, and
0.1mg/ml streptomycin were used for propagation of HSV-1.
Pseudorabies virus (PRV) strain YS-81 and a cellular clone
of the porcine kidney cell line (CPK) were kindly provided
by M. Shimizu (National Institute of Animal Health, Tsu-
kuba, Japan). CPK cells, grown in Eagle’s minimum essen-
tial medium (MEM) supplemented with 10% calf serum,
0.03% L-glutamine, 0.03% tryptose phosphate broth, nones-
sential amino acids (Flow Laboratories, Costa Mesa, CA),
vitamins (Flow Laboratories), 100 U/ml penicillin, and 0.1
mg/ml streptomycin, were used for propagation of PRV. Vero
cells were also used for plaque assay. COS7 cells, grown in
Dulbecco’s modified Eagle medium (DMEM; Sigma Co., St.
Louis, MO) supplemented with 10% fetal bovine serum,
0.03% L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin were used for preparation of HVEMIg.
Preparation of HVEMIg
To prepare a soluble form of HVEM (HVEMIg), an
adenovirus vector containing a chimeric gene that encodes
a fusion protein consisting of an extracellular domain of
murine HVEM and the Fc portion of human IgG1 was
constructed. The extracellular domain of HVEM cDNAwas
amplified by using RT-PCR, in which an mRNA isolated
from Con A-stimulated splenocytes obtained from BALB/c
mouse was used as a template. The PCR primers used to
amplify the cDNA were 5V-TAACTCGAGCTCTTGGCCT-
GAAGTTTC-3V and 5V-TTAAGGATCCGAGGAGCA-
GGTGGTGTCT-3V. The cDNA was inserted into the XhoI
and BamHI sites of a plasmid carrying IgG1-Fc DNA
(Nakagawa et al., 1998), and verified the sequence. Then,
the plasmid was digested with XhoI and XbaI to obtain the
HVEMIg DNA fragment. The fragment was blunt-ended and
was inserted into a SwaI site of pAxCAwt cosmid vector
(Takara, Kyoto, Japan) to prepare the recombinant adenovi-
rus (AxHVEMIg). The recombinant adenovirus was prepared
using Adenovirus Expression Vector Kit (Takara) according
to the protocol supplied by manufacturer. HVEMIg was
purified from a supernatant of COS7 cells infected with
AxHVEMIg. Briefly, semi-confluent COS7 cells were
washed and infected with AxHVEMIg. After 4 days culture,
the supernatant was recovered for the purification of HVE-
MIg. HVEMIg was purified from the supernatant by Protein
A-Sepharose 4FF (Amersham Pharmacia Biotech, Buck-
inghamshire, England) affinity chromatography (Takiguchi
et al., 1999).
Transgenic mice
The PmeI–SalI transgene fragments containing the CAG
promoter (cytomegalovirus IE enhancer and chicken h-actin
promoter), the HVEMIg gene, and the rabbit h-globin polyA
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microinjected into C57BL/6 X SJL F2 hybrid mouse eggs to
create transgenic mice in Chrysalis DNX Transgenic Scien-
ces Corporation (Princeton, NJ). Transgenic founders were
identified by PCR using genomic DNA isolated from mouse
tail (Hogan et al., 1986) and the specific primers (5V-GCCT-
CTGCTAACCATGTTCATGCCT-3V and 5V-TGTGCT-
GCAAGCATGTGGAACAGTG-3V), which resulted in the
amplified fragment of 573 bp. The transgenic founders were
crossed with C57BL/6 mice until we obtained the third (F3)
generation. Each heterozygous of the F3 progeny crossed
with C57BL/6 mice and their offspring were used for the
experimental infection. All mice were maintained in the
animal facility at our institute and treated according to the
Laboratory Animal Control Guidelines of our institute,
which basically conformed to those of the National Institutes
of Health-American Association of Laboratory Animal
Control.
Analysis of the transgene expression
To detect HVEMIg in sera of the transgenic mice, poly-
clonal antibodies against HVEMIg were raised in NZW
rabbit immunized with the purified HVEMIg. Whole serum
was collected and used as anti-HVEMIg antibody. To mea-
sure HVEMIg concentrations in sera of the transgenic mice, a
competitive ELISA system was established. The 96-well
plate was coated with 5 Ag/ml HVEMIg then treated with
1% BSA solution to block nonspecific protein binding. Both
of serum sample and 106-fold diluted anti-HVEMIg antibody
were added into the well simultaneously and incubated for 1
h. After washing the wells, 104-fold diluted peroxidase-
labeled goat anti-rabbit IgG (BIO-RAD Laboratories, Her-
cules, CA) was added and then visualized antibody binding
by using o-phenylenediamine as a substrate. Serially diluted
HVEMIg were used for making a standard curve.
Western blotting was performed by the method of Towbin
et al. (1979). Ten microliters of each extract from tails of the
transgenic mice was separated by 12% SDS-polyacrylamide
gel electrophoresis. The separated proteins were then elec-
trophoretically transferred to Immobilon transfer membrane
(Millipore, Bedford, MA). The sheet was treated sequentially
with a Block Ace (Snow Brand Milk Products, Sapporo,
Japan), 500-fold diluted anti-HVEMIg antibody, and finally
with peroxidase-labeled goat anti-rabbit IgG. The antigen
was detected using Renaissance Reagent (DuPont NEN
Research Products, Boston, MA) as a substrate.
Virus infection in mice
Groups of adult (7 weeks old) C57BL/6 and SJL mice
were inoculated intravenously with 100 Al aliquots of serial
10-fold dilutions of HSV-1 strain VR-3 and the survival rate
was assessed daily for 14 days. The 50% lethal doses (LD50)
of the virus strain in each mouse strain were determined
graphically. Transgenic and non-transgenic offspring of theF3 progeny were used when they were 7 weeks old. To verify
the transgene expression, sera of the mice were collected
before the experimental infection. The mice were infected
intravenously with 100 Al of phosphate-buffered saline
(PBS) containing 10 LD50 (viral dose determined on
C57BL/6 mice) of HSV-1. Survival of mice and signs of
disease were recorded for 14 days. The transgene expression
was verified by the competitive ELISA after the experimen-
tal infection was finished. Experimental infection with PRV
was also performed using the transgenic and C57BL/6 mice
as described above.
To test for protection of the mice after inoculation of
mucosa, the mice were infected intranasally with 5 Al of
PBS containing 104 PFU of HSV-1 under anesthesia.
Trigeminal ganglia were obtained 14 days after the virus
inoculation to detect LATs expression by RT-PCR.
Histopathological procedure
Mice were killed by decapitation after the termination of
the experiments at day 14. Tissue samples from decapitated
animals were excised and immersion-fixed in Bouin’s
solution for 24 h at room temperature, embedded in paraffin
wax, and cut into 5-Am-thick slices with a microtome.
Sections were stained with hematoxylin and eosin.
Detection of LATs in trigeminal ganglia by RT-PCR
Survived mice were killed by decapitation and trigeminal
ganglia were immediately removed and frozen in liquid
nitrogen. Total cellular RNAwas isolated from the trigeminal
ganglia using TriZOL reagent (Invitrogen, Grand Island,
NY). For RT-PCR analysis, 1 Ag of total RNAwas digested
with RNase-free DNaseI (Invitrogen) to remove any con-
taminating genomic DNA. The cDNAwas synthesized from
the DNaseI-treated total RNA by MMLV reverse transcrip-
tase (Invitrogen) using ICP0-3V(Iwai et al., 1991) as a LAT-
specific primer. The PCR reaction was carried out as de-
scribed by Halford et al. (1996). Control samples without the
reverse transcriptase reaction were amplified in parallel to
confirm the absence of genomic DNA contamination. The
PCR products were fractionated on 1.5% agarose gel and
transferred to Hybond N+ membranes (Amersham Pharma-
cia Biotech, Uppsala, Sweden) by capillary blotting. Digox-
igenin (DIG)-labeled DNA probes for detection of LATs
were derived from pSLAT2 (Lachmann et al., 1996) using
the specific primers LAT-a and LAT-b (Lynas et al., 1989)
and a PCR DIG probe synthesis kit (Roche Diagnostics,
Mannheim, Germany). Hybridization and detection of LATs
were performed as described previously (Ono et al., 1999).
Competition of the virus infectivity with HVEMIg
Vero cells were plated at a subconfluent density on 35-
mm dishes and cultured for 24 h. The following day, 5 Al of
serum sample was incubated with 50 PFU of HSV-1 or PRV
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with DMEM, each sample containing viruses was absorbed
to Vero cells at 37 jC for 1 h. Viruses were removed and
then overlaid with DMEM containing 0.5% agarose (Sig-
ma). Plaques were counted 3–4 days after infection.
Virus infection in mouse embryonic fibroblasts
Transgenic and non-transgenic mice (embryonic day 14)
were killed by decapitation, and the embryonic fibroblasts
were isolated by dicing the mouse embryos, stirring the
pieces for 30 min at room temperature in PBS supplemented
with 0.25% trypsin and then plating out the resulting single
cell suspension. The cells were grown in DMEM supple-
mented with 10% fetal bovine serum and the above anti-
biotics. The cells were passed no more than twice before
use. To detect HVEMIg, the mouse embryonic fibroblasts
were plated at a subconfluent density on 60-mm dishes. The
following day, the cells were lysed in the sample buffer.
Aliquots of the extracts were applied onto 12% SDS-
polyacrylamide gels and electrophoresed. Western blotting
was performed as described above.
For the plaque assay, the mouse embryonic fibroblasts
were plated at a subconfluent density on 35-mm dishes. The
following day, 50 PFU of HSV-1 or PRV was adsorbed onto
the cells. After 1 h, the cells were washed twice with DMEM
and then overlaid with agar described above. The cells were
stained 3–4 days after infection. To monitor virus growth in
the mouse embryonic fibroblasts, the cells were plated at a
subconfluent density on 60-mm dishes. The following day,
0.01 PFU/cell of HSV-1 or PRV was adsorbed onto the cells.
After 1 h, the cells were washed twice with DMEM and then
maintained in 5 ml of DMEM. Supernatant was removed at
24-h intervals. Virus titers of supernatant samples were
determined on Vero cell monolayers.Acknowledgments
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